12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PSI-7977: Phase II started

Medivir AB (SSE:MVIR B, Huddinge, Sweden) disclosed in its 4Q11 earnings that Janssen R&D Ireland (formerly Tibotec Pharmaceuticals Ltd.) began an open-label, U.S. Phase II trial to evaluate 150 mg TMC435 daily in combination with 400 mg GS-7977 daily with...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >